Explore more publications!
Louisiana Health Daily
Got News to Share?

Louisiana Health Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Louisiana Health Daily.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on October 7, 2025

Extendicare Announces Timing of 2025 Third Quarter Results and Conference Call
October 7, 2025

Extendicare Announces Timing of 2025 Third Quarter Results and Conference Call

Indeterminate GlobeNewswire
Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
October 7, 2025

Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

Indeterminate GlobeNewswire
MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
October 7, 2025

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Indeterminate GlobeNewswire
CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer
October 7, 2025

CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer

Indeterminate GlobeNewswire
Microbot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
October 7, 2025

Microbot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds

Indeterminate GlobeNewswire
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025
October 7, 2025

Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025

Indeterminate GlobeNewswire
Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025
October 7, 2025

Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025

Indeterminate GlobeNewswire
Biomea Fusion Announces Pricing of Public Offering of Securities
October 7, 2025

Biomea Fusion Announces Pricing of Public Offering of Securities

Indeterminate GlobeNewswire
Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter
October 7, 2025

Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter

Indeterminate GlobeNewswire
Esaote enters the field of neurosurgery by presenting an innovative intraoperative MRI system
October 7, 2025

Esaote enters the field of neurosurgery by presenting an innovative intraoperative MRI system

Indeterminate GlobeNewswire
Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada
October 7, 2025

Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada

Indeterminate GlobeNewswire
Thérapeutique Knight annonce la relance de MYFEMBREE® au Canada
October 7, 2025

Thérapeutique Knight annonce la relance de MYFEMBREE® au Canada

Indeterminate GlobeNewswire
Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01
October 7, 2025

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

Indeterminate GlobeNewswire
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases
October 7, 2025

Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases

Indeterminate GlobeNewswire
Biomed Valley Discoveries Announces Publication of Results from Phase 1b Study of Pembrolizumab in Combination with Clostridium novyi-NT (CNV-NT/BVD-550) in Patients with Advanced Solid Tumors in Clinical Cancer Research
October 7, 2025

Biomed Valley Discoveries Announces Publication of Results from Phase 1b Study of Pembrolizumab in Combination with Clostridium novyi-NT (CNV-NT/BVD-550) in Patients with Advanced Solid Tumors in Clinical Cancer Research

Indeterminate GlobeNewswire
Coave Therapeutics demonstrates superiority of its novel suprachoroidal capsid at ESGCT Congress 2025
October 7, 2025

Coave Therapeutics demonstrates superiority of its novel suprachoroidal capsid at ESGCT Congress 2025

Indeterminate GlobeNewswire
OXB expands US footprint with acquisition of commercial-scale viral vector facility in North Carolina
October 7, 2025

OXB expands US footprint with acquisition of commercial-scale viral vector facility in North Carolina

Indeterminate GlobeNewswire
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
October 7, 2025

Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3

Indeterminate GlobeNewswire
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
October 7, 2025

Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity

Indeterminate GlobeNewswire
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences
October 7, 2025

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions